Macrophage Inhibitory Cytokine-1 (MIC-1) as A Biomarker for Diagnosis 
and Prognosis of Stage I-II Non-small Cell Lung Cancer

• Published in: Zhongguo fei ai za zhi Vol. 19; no. 4; pp. 207 - 215
• Main Authors: Liu, Yuning, Wang, Xiaobing, Wang, Teng, Zhang, Chao, Zhang, Kunpeng, Zang, Ruochuan, Zhi, Xiuyi, Zhang, Wei, Sun, Kelin
• Format: Journal Article
• Language: Chinese
• Published: China Chinese Anti-Cancer Association Chinese Antituberculosis Association 01.04.2016; Chinese Anti-Cancer Association; Chinese Antituberculosis Association
• Subjects: Adult; Aged; Biomarkers, Tumor - blood; Cancer therapies; Carcinoma, Non-Small-Cell Lung - blood; Carcinoma, Non-Small-Cell Lung - diagnosis; Carcinoma, Non-Small-Cell Lung - mortality; Carcinoma, Non-Small-Cell Lung - pathology; Chemotherapy; Cytokines; Female; Growth Differentiation Factor 15 - blood; Humans; Lung cancer; Lung neoplasms; Lung Neoplasms - blood; Lung Neoplasms - diagnosis; Lung Neoplasms - mortality; Lung Neoplasms - pathology; Macrophage inhibitory cytokine-1; Male; Medical prognosis; Medical screening; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Radiation therapy; Surgery; Thoracic surgery; Tumor biomarker; Young Adult; Beijing China; China
• ISSN: 1009-3419; 1999-6187
• DOI: 10.3779/j.issn.1009-3419.2016.04.05

Increased macrophage inhibitory cytokine-1 (MIC-1), member of transforming growth factor-β (TGF-β) superfamily, was found in patients serum with epithelial tumors. Therefore, our aim was to delineate the diagnostic and prognostic value of serum MIC-1 in patients with stage I-II non-small cell lung cancer (NSCLC). A total of 152 consecutive patients with stage I-II NSCLC were prospectively enrolled and underwent follow up after total resection of tumor. Serum MIC-1 level was detected in lung cancer patients by ELISA, 48 benign pulmonary disease patients and 105 healthy controls, and was correlated with clinical features and prognosis of patients. The level of MIC-1 of NSCLC patients was significantly higher than that of controls (P<0.001) and benign pulmonary disease patients (P<0.001). A threshold of 1,000 pg/mL could be used to diagnose early-stage NSCLC with 70.4% sensitivity and 99.0% specificity. The level of MIC-1 was associated with elder age (P=0.001), female (P=0.03) and T2 (P=0.022). A threshold of 1